EX-15.2 15 ex152ey2020consent.htm EX-15.2

Ernst & Young LLP 2200, 215 2nd St SW Calgary, AB T2P 1M4 |  | Tel: +1 403 206 5000 Fax: +1 403 290 4265 ey.com/ca

EXHIBIT 15.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use of our reports dated March 4, 2021 with respect to the consolidated financial statements of Oncolytics Biotech Inc. (“Oncolytics”) as at December 31, 2020 and 2019 and for each of the years in the three year period ended December 31, 2020 included as an exhibit to or incorporated by reference in the Annual Report (Form 20-F) for 2020.
We also consent to the incorporation by reference in the Registration Statement on Form F-10 (Nos. 333-239025) and Registration Statements on Form S-8 (Nos. 333-171625 and 333-205708) of our report dated March 4, 2021 with respect to the consolidated financial statements of Oncolytics as at December 31, 2020 and 2019 and for each of the years in the three year period ended December 31, 2020 included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2020, as filed with the SEC.

Calgary, Alberta | /s/Ernst & Young LLP
March 5, 2021 | Chartered Professional Accountants

A member firm of Ernst & Young Global Limited